GHK-Cu in 2026 — A Formulator's Field Guide to Copper Tripeptide-1

Copper Tripeptide-1 — INCI name for GHK-Cu — is the most-cited cosmetic peptide active on the planet, and also the one most likely to behave unexpectedly in a finished product. This Field Guide walks through the formulation decisions a chemist actually makes when bringing GHK-Cu into a serum, cream, or eye-area formulation, and the small list of incompatibilities that account for most "the peptide didn't work" support tickets in this class.

The chemistry, in two paragraphs

GHK-Cu is a copper-binding tripeptide consisting of glycyl-L-histidyl-L-lysine bound to a divalent copper ion through the imidazole nitrogen of histidine and two backbone amide nitrogens, forming a roughly square-planar tetraamine field around the metal. The complex was originally isolated from human plasma in 1973 and is the textbook example of an endogenous copper-peptide complex. The visible blue colour of the lyophilised powder and reconstituted solutions is the d-d electronic transition of the bound Cu(II) — and the diagnostic visual signal that the complex is intact.

The biological signature that motivates GHK-Cu's use in cosmetic formulation — dermal-repair signalling, fibroblast activation, anti-aging effects in finished products — is the property of the intact complex. Free GHK on its own and free Cu²⁺ on its own do not reproduce it. The first rule of formulating with GHK-Cu is therefore: keep the copper on the peptide.

INCI Quick Facts

• INCI name: Copper Tripeptide-1
• CAS: 89030-95-5 (the complex)
• MW: 401.91 (complex); 340.38 (free peptide)
• Recommended use level: 0.5–2 % finished mass for general anti-aging serums; 0.1–0.5 % for eye-area and sensitive-skin products; 0.5–1 % for night creams
• Working pH range: 5.5–7.0
• Storage as supplied: −20 °C in original packaging, protected from light

Use level — the lower-is-better principle

GHK-Cu is potent at remarkably low concentrations. Published cosmetic formulations cluster between 0.5 % and 2 % finished mass for anti-aging serums; higher levels do not produce proportionally larger effects and start to cause cosmetic problems (visible blue tint in the finished product that the brand often does not want). The right starting point for a new formula is the low end of the published range, then escalating only if the carrier matrix reduces bioavailability of the active.

For eye-area products where stability and sensory feel matter most, 0.1–0.5 % is the working range. For night creams with heavy oil-phase fractions, 0.5–1 % is typical because the aqueous-phase concentration is what determines the active load on skin.

Carrier selection

GHK-Cu performs best in chelator-free aqueous or hydroglycerin carriers. Three carrier families that work reliably:

• Aqueous serum (5–15 % glycerin + water + viscosity modifier): the canonical GHK-Cu vehicle. Stable, predictable, easy to scale.
• Lipid-encapsulated (liposomal, micellar, or vesicle systems): improves dermal penetration and reduces the visible blue tint in higher-load products; adds formulation complexity.
• Hydroglycerin emulsion with low oil phase (5–10 % oil): suitable for night creams; the GHK-Cu sits in the aqueous phase, oil phase delivers occlusion + sensory feel.

Carrier families that require additional stability work:

• Heavy emulsions (oil-in-water above 20 % oil) — the aqueous-phase Cu(II) can interact with fatty-acid impurities in the oil phase; specify pharmaceutical-grade oil suppliers.
• Anhydrous balms — GHK-Cu needs water for the coordination chemistry to behave; anhydrous systems generally do not deliver the active.

The incompatibility shortlist

Four classes of ingredients drive most of the failure modes formulators see in GHK-Cu finished products. Each one operates by a different mechanism but all four reduce the bound-Cu fraction over the finished product's shelf life:

• Chelators — EDTA, disodium EDTA, calcium disodium EDTA, and any preservative blend that lists EDTA as a component. These sequester Cu²⁺ away from the peptide. EDTA is the single most common chelator-contamination source in cosmetic formulations because it appears in many preservative systems by default. Audit every preservative against its ingredient list. Citrate at high concentrations (above ~0.5 %) is a milder chelator and worth watching.
• High-concentration reductive antioxidants — particularly ascorbic acid (vitamin C) above ~5 % finished mass. The reduction Cu(II) → Cu(I) changes coordination preferences and abolishes the GHK-Cu signature. Either keep ascorbic acid below 3 % when co-formulating with GHK-Cu, or place them in separate-phase products (e.g. AM vitamin C, PM GHK-Cu).
• Low pH — the histidine imidazole becomes protonated below pH ~4.5, disrupting the coordination sphere. AHA / BHA exfoliants at their working pH (3.5–4.0) are incompatible with GHK-Cu in the same formula. The two can coexist in the same routine, but not in the same bottle.
• Strong oxidising preservatives — peroxide-based preservatives, high-percentage benzoyl peroxide, hypochlorite. These oxidise the peptide directly. Avoid in any GHK-Cu finished product.

pH and stability

The complex is stable across pH 5.5–7.0 with negligible degradation over a 12-month shelf life when stored at room temperature in a chelator-free aqueous carrier with a standard cosmetic preservative system. Outside that window, expect the following:

• Below pH 5 — gradual loss of the d-d band (visible as the formula going from blue to pale-blue to colourless over weeks). The free peptide is still present but the active form is gone.
• Above pH 8 — Cu(II) hydrolyses out of the coordination sphere; precipitation of copper hydroxide is sometimes visible in the finished product.

For stability work in your specific carrier matrix, the 12-month real-time + 3-month accelerated (40 °C / 75 % RH) protocol is the standard cosmetic-industry envelope. Pepoderma's lot report carries the active's stability data in a reference aqueous-serum carrier; for stability in your own carrier matrix, the Formulation Lab page publishes the protocol template.

Three reference formulations

Three starting-point formulations that have been validated by other Pepoderma brand partners — use these as starting frames, then tune to your brand's sensory and packaging goals:

1. Daily anti-aging serum - Aqueous phase: water q.s. + 8 % glycerin + 3 % propanediol - Viscosity: 0.4 % xanthan gum (or 0.5 % HEC) - pH adjusted to 6.0 with citric acid / sodium hydroxide - Active: 1 % Copper Tripeptide-1 (Pepoderma GHK-Cu) - Preservative: 1 % phenoxyethanol-free system (e.g. ethylhexylglycerin + caprylyl glycol + benzoic acid) - Optional skin-feel: 1 % sodium hyaluronate (low molecular weight)

2. Eye-area gel - Aqueous phase: water q.s. + 10 % glycerin - Viscosity: 0.3 % carbomer + 0.1 % triethanolamine (pH adjuster) - pH adjusted to 6.0 - Active: 0.3 % Copper Tripeptide-1 - Co-active: 0.5 % AHK-Cu (hair-scalp variant repurposed for periocular) - Preservative: phenoxyethanol-free system

3. Night cream with low oil phase - Aqueous phase: water q.s. + 6 % glycerin - Oil phase: 8 % squalane + 4 % jojoba ester (chelator-free, food-grade) - Emulsifier: 3 % cetearyl alcohol + glyceryl stearate - Viscosity: 0.3 % xanthan gum - pH adjusted to 6.5 - Active: 0.8 % Copper Tripeptide-1 - Preservative: phenoxyethanol-free system

What to ask your supplier (every supplier, not just us)

Three questions that separate a serious cosmetic-peptide supplier from a generic catalogue vendor:

1. Can you supply the lot's Cu²⁺ : peptide molar ratio measurement, not just the HPLC purity? (Mass purity does not tell you about copper coordination.)
2. Can you supply stability data of this lot in a reference aqueous serum, not just in the lyophilised state? (Your finished product is the solution, not the powder.)
3. Can you flag incompatibility with the preservative system in my finished formula? (This is where supplier-side formulation support actually pays off.)

Every Pepoderma GHK-Cu lot ships with the molar-ratio measurement on the lot report, the reference-serum stability data, and a flag list of preservative-system incompatibilities for the carrier you specify at quote stage.